Biogen Reports First Quarter 2017 Revenues of $2.8 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Biogen (BIIB) PT Raised to $280 at Stifel
April 25, 2017 11:18 AM EDTStifel analyst Thomas Shrader raised his price target on Biogen (NASDAQ: BIIB) to $280.00 (from $265.00) while maintaining a Hold rating following results this morning.
The analyst noted the results were positive for the companys goal to trim some of the fat from... More
Biogen (BIIB) Tops Q1 EPS by 20c
April 25, 2017 7:00 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $5.20, $0.20 better than the analyst estimate of $5.00. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.74 billion.
Total revenues of $2.8 billion, a 3% increase versus the prior year and an 8% increase excluding hemophilia... More